Maldonado-GarcÃa, J.L.; GarcÃa-Mena, L.H.; Mendieta-Cabrera, D.; Pérez-Sánchez, G.; Becerril-Villanueva, E.; Alvarez-Herrera, S.; Homberg, T.; Vallejo-Castillo, L.; Pérez-Tapia, S.M.; Moreno-Lafont, M.C.;
et al. Use of Extracellular Monomeric Ubiquitin as a Therapeutic Option for Major Depressive Disorder. Pharmaceuticals 2024, 17, 841.
https://doi.org/10.3390/ph17070841
AMA Style
Maldonado-GarcÃa JL, GarcÃa-Mena LH, Mendieta-Cabrera D, Pérez-Sánchez G, Becerril-Villanueva E, Alvarez-Herrera S, Homberg T, Vallejo-Castillo L, Pérez-Tapia SM, Moreno-Lafont MC,
et al. Use of Extracellular Monomeric Ubiquitin as a Therapeutic Option for Major Depressive Disorder. Pharmaceuticals. 2024; 17(7):841.
https://doi.org/10.3390/ph17070841
Chicago/Turabian Style
Maldonado-GarcÃa, José Luis, Lissette Haydee GarcÃa-Mena, Danelia Mendieta-Cabrera, Gilberto Pérez-Sánchez, Enrique Becerril-Villanueva, Samantha Alvarez-Herrera, Toni Homberg, Luis Vallejo-Castillo, Sonia Mayra Pérez-Tapia, Martha C. Moreno-Lafont,
and et al. 2024. "Use of Extracellular Monomeric Ubiquitin as a Therapeutic Option for Major Depressive Disorder" Pharmaceuticals 17, no. 7: 841.
https://doi.org/10.3390/ph17070841
APA Style
Maldonado-GarcÃa, J. L., GarcÃa-Mena, L. H., Mendieta-Cabrera, D., Pérez-Sánchez, G., Becerril-Villanueva, E., Alvarez-Herrera, S., Homberg, T., Vallejo-Castillo, L., Pérez-Tapia, S. M., Moreno-Lafont, M. C., Ortuño-Sahagún, D., & Pavón, L.
(2024). Use of Extracellular Monomeric Ubiquitin as a Therapeutic Option for Major Depressive Disorder. Pharmaceuticals, 17(7), 841.
https://doi.org/10.3390/ph17070841
